Clay Siegall Ph.D. is a man with an impressive and inspiring story of achievements, and dedication. He is the co-founder, CEO, and chairman of Seattle Genetics, which has been in business since 1998. He saw his father battle cancer and eventually succumb to it, which is why he dedicated himself to fighting cancer. While studying at the University of Maryland, his advisers shared a curiosity about cancer treatment. This background explains how he considered a path towards research. An internship at the National Institute of Health opened up a pathway to his goal. He later attended George Washington University to pursue his Ph.D.
Clay founded Seattle Genetics with a vision of developing innovative biotechnological research with the aim of helping patients. The company has several licenses including with Pfizer. Under the leadership of Dr. Siegall, the company has generated more than $1.2 billion through public and private funding. The funding has allowed the company to continue to be a trail blazer in advancing cancer treatment through innovative technology.
Clay’s scientific mind and visionary leadership make him a rare individual. He is propelling his company and also the entire industry to new heights. Under Dr. Clay Siegall, the company has entered into multiple strategic licenses for their ADC technology. The move has, in turn, made them industry leaders in the field of antibody drug conjugates. With the FDA approval of the companies first ADC product, Adcentris, the company has generated more than $350 million in sales to date. The drug is now approved in more than 65 countries, adding to Clay’s success.
Imagine going to work every day and seeing the people who the drug you developed has saved. It is a fantastic atmosphere to work. Dr. Siegall is looking more determined every day, and the individuals who are working with him are motivated to do more to help the patients. The inspiring atmosphere at Seattle Genetics makes for the perfect conditions to pursue the fight against cancer. Dr. Siegall currently holds 15 patents and is always pushing the boundaries to better treatment. He has published more than 70 publications to contribute to the medical and scientific community.